✦ LIBER ✦

PCN24 OVERALL SURVIVAL AND DOCETAXEL TREATMENT CYCLES IN PATIENTS WITH METASTATIC PROSTATE CANCER – RESULTS FROM A US ONCOLOGY NETWORK

✍ Scribed by H Chung; L Chen; NP Christiansen; SD Sullivan

Book ID: 118609799
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 69 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)72114-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN23 OVERALL SURVIVAL AND GAP IN DOCETA

PCN23 OVERALL SURVIVAL AND GAP IN DOCETAXEL TREATMENT CONTINUATION IN PATIENTS WITH METASTATIC PROSTATE CANCER – RESULTS FROM A US ONCOLOGY NETWORK

✍ H Chung; L Chen; SD Sullivan; NP Christiansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PCN125 NUMBER OF DOCETAXEL TREATMENT CYC

PCN125 NUMBER OF DOCETAXEL TREATMENT CYCLES AND OVERALL SURVIVAL FOR METASTATIC PROSTATE CANCER–RESULTS FROM A US LOCAL COMMUNICTY PRACTICE

✍ L Zhao; B Seal; M Tangirala; SD Sullivan; NP Christiansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Association of pretreatment neutrophil-t

Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel

✍ Nuhn, Philipp; Vaghasia, Ajay M.; Goyal, Jatinder; Zhou, Xian C.; Carducci, Mich 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th

PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOM

PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONEREFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL

✍ M Mason; N Freemantle; A Parnaby; D Högberg 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB